JOHN CZAJKOWSKI, NCI deputy director for management, has accepted a position as executive dean of administration at Harvard Medical School. His start date will be June 2.
ISSAM MAKHOUL was named the inaugural recipient of the Laura F. Hutchins, M.D. Distinguished Chair for Hematology and Oncology at the University of Arkansas for Medical Sciences.
AVEO ONCOLOGY and Astellas Pharma Inc. will end an agreement to develop the investigational cancer drug tivozanib by Aug. 11.
JIM ALLISON has been awarded the 2014 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.
THE AMERICAN CANCER SOCIETY added five new officers to its 2014 national volunteer board of directors. Pamela Meyerhoffer, a 40-year volunteer with the society, will chair the new board.
JOHN WALTER, president and CEO of The Leukemia & Lymphoma Society since 2008, has stepped down.
FRASER SYMMANS was named director of the CALGB Alliance Translational Research Program. He will oversee the activities of all scientific and administrative committees.
WAUN KI HONG announced his plans to retire as head of the MD Anderson Cancer Center Division of Cancer Medicine effective this summer after 30 years at that institution. Hong is 71.
AMGEN and MERCK announced an agreement to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a phase Ib/II study in mid- to late-stage melanoma.
HEALTH CANADA approved the Aptima HPV 16 18/45 genotype assay for use on the Panther system, both developed by Hologic Inc. The assay is the only approved test for genotyping human papillomavirus types 16, 18 and/or 45 in Canada.
